Tianjin Second People's Hospital Report issue

Academic/Hospital Phase 3 Phase 4

Organization Overview

First Clinical Trial
2019
NCT04028323
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Tianjin Second People's Hospital

Active Ingredients

Drugs in Phase 4 Trials (3)

octreotide (sandostatin) (1 trial)

tenofovir alafenamide (genvoya) (1 trial)

terlipressin (Terlivaz) (1 trial)

Drugs in Phase 3 Trials (2)

berberine (1 trial)

carvedilol (coreg) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Fibrosis (Phase 3)

Hemorrhage (Phase 4)

Hepatitis (Phase 3)

Hepatitis A (Phase 3)

Hepatitis B (Phase 3)

Hepatitis C (Phase 3)

Liver Cirrhosis (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 3
  • # of Trial APIs: 5